HPE Chronic pain – part two | Page 10

References 1 Schug SA. Opioids: Clinical use. In: McMahon SB et al (eds) Wall & Melzack’s Textbook of Pain. 6th edn. Amsterdam: Elsevier; 2013. 2 Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011–14. 3 Hughes J et al. Identification of two related pentapeptides from the brain with potent opioid agonist activity. Nature 1975;258:577–80. 4 Macintyre PE, Loadsman JA, Scott DA. Opioids, ventilation and acute pain management. Anaesth Intensive Care 2011;39(4):545–58. 5 Bannister K. Opioid-induced hyperalgesia: where are we now? Curr Opin Support Palliat Care 2015;9(2):116–21. 6 O’Rourke TK Jr, Wosnitzer MS. Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, management, and literature review. Curr Urol Rep 2016;17(10):76. 7 Ninkovic J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids 2013;45(1):9–24. 8 Wiese AD et al. Opioid analgesic use and risk for invasive pneumococcal diseases: A nested case-control study. Ann Intern Med 2018;168(6):396–404. 9 Vowles KE et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156(4):569–76. 10 Lee J et al. Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6. Drug Des Devel Ther 2019;13:1751–61. 11 Raffa RB et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther 1992;260(1):275–85. 12 Raffa RB. On subclasses of opioid analgesics. Curr Med Res Opin 2014;30(12):2579–84. 13 Desmeules JA et al. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996;41(1):7–12. 14 Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43(13): 879–923. 15 Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Rev 1996;3:249–71. 16 Murphy JD et al. Comparison of the postoperative analgesic efficacy of intravenous patientcontrolled analgesia with tramadol to intravenous patientcontrolled analgesia with opioids. J Opioid Manage 2010;6(2):141–7. 17 Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep 2009;61(6):978–92. 18 Rosenberg MT. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009;63(10):1531–43. 19 Cepeda MS et al. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol 2007;34(3):543–55. 20 Duehmke RM et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD003726. 21 Tarkkila P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and oxycodone. J Clin Anesth 1997;9(7):582–5. 22 Tarkkila P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and pethidine. Eur J Anaesthesiol 1998;15(1):64–8. 23 Mildh LH, Leino KA, Kirvela OA. Effects of tramadol and meperidine on respiration, plasma catecholamine concentrations, and hemodynamics. J Clin Anesth 1999;11(4):310–16. 24 Warren PM et al. Influence of tramadol on the ventilatory response to hypoxia in humans. Br J Anaesth 2000;85(2):211–16. 25 Hassanian-Moghaddam H et al. Tramadol-induced apnea. Am J Emerg Med 2013;31(1):26–31. 26 Tsai YC, Won SJ. Effects of tramadol on T lymphocyte proliferation and natural killer cell activity in rats with sciatic constriction injury. Pain 2001;92(1-2):63–9. 27 Sacerdote P et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000;90(6): 1411–14. 28 Sansone RA, Sansone LA. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont) 2009;6(4):17–21. 29 Hassamal S et al. Tramadol: Understanding the risk of serotonin syndrome and seizures. Am J Med 2018;131(11):1382. e1-1382.e6. 30 Miotto K et al. Trends in tramadol: Pharmacology, metabolism, and misuse. Anesth Analg 2017;124(1):44–51. 31 Brouquet A et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg 2010;251(4):759–65. 32 Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81(3):429–44. 33 Fliegert F, Kurth B, Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 2005;61(4):257–66. 34 Stamer UM et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105 (1-2):231–8. 35 Stamer UM et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008;107(3):926–9. 36 Faria J et al. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain 2018;22(5):827–44. 37 Gressler LE, Hammond DA, Painter JT. Serotonin syndrome in tapentadol literature: Systematic review of original research. J Pain Palliat Care Pharmacother 2017;31(3-4):228–36. 38 Tzschentke TM, Christoph T, Kogel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014;28(4):319–29. 39 Christoph T et al. Spinalsupraspinal and intrinsic mu-opioid receptor agonistnorepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 2013;347(3):794–801. 40 Niesters M et al. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth 2014;113(1):148–56. 41 Lange B et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27(6):381–99. 42 Wiffen PJ et al. Oral tapentadol for cancer pain. Cochrane Database Syst Rev 2015;9:CD011460. 43 Vinik AI et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 2014;37(8):2302–09. 44 Xiao JP et al. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: A systematic review and metaanalysis. Pain Med 2017;18(1): 14–24. 45 Sánchez del Águila M et al. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther 2015;37:94–113. 46 van der Schrier R et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br J Anaesth 2017;119(6):1169–77. 47 Baron R et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/ naloxone PR in patients with severe chronic low back pain with a neuropathic component: A randomized, controlled, openlabel, Phase 3b/4 trial. Pain Pract 2016;16(5):600–19. 48 Meng Z et al. Tolerability of opioid analgesia for chronic pain: A network meta-analysis. Sci Rep 2017;7(1):1995. 49 Franchi S et al. Effect of tapentadol on splenic cytokine production in mice. Anesth Analg 2017;124(3):986–95. 50 Cowan A. Buprenorphine: the basic pharmacology revisited. J Addict Med 2007;1(2):68–72. 51 Khanna IK, Pillarisetti S. Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res 2015;8:859–70. 52 Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13(3):219–30. 53 Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012;10(6):209–19. 54 Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med 2014;15(7):1171–8. 55 Li X, Shorter D, Kosten TR. Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies. Expert Opin Pharmacother 2014;15(15):2263–75. 56 Vlok R et al. Sublingual buprenorphine versus intravenous or intramuscular morphine in acute pain: A systematic review and meta-analysis of randomized control trials. Am J Emerg Med 2019;37(3):381–6. 57 Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003;63(19):1999–2010; discussion 1–2. 58 Dahan A et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005;94(6):825–34. 59 Dahan A et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96(5):627–32. 60 Selden T et al. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci Int 2012;220(1-3):284–90. 61 Coplan PM et al. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. Postgrad Med 2017;129(1):55–61. 62 Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005;27(7):1022–31. 63 Koppert W et al. Different profiles of buprenorphineinduced analgesia and antihyperalgesia in a human pain model. Pain 2005;118(1-2):15–22. 64 Mercieri M et al. Lowdose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial. Br J Anaesth 2017;119(4):792–802. 65 Watkins LR et al. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009;30(11): 581–91. 66 Van Loveren H et al. Assessment of immunotoxicity of buprenorphine. Lab Anim 1994;28(4):355–63. 67 Gomez-Flores R, Weber RJ. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology 2000;48(2):145–56. 68 Bliesener N et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005;90(1):203–6. 69 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006;260(1):76–87. 70 Lavonas EJ et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat 2014;47(1): 27–34. 71 Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘mu-load’. Adv Ther 2018;35(10):1471–84. 10 | 2020 | hospitalpharmacyeurope.com